Rodriguez-Barradas Maria C, Goulet Joseph, Brown Sheldon, Goetz Matthew Bidwell, Rimland David, Simberkoff Michael S, Crothers Kristina, Justice Amy C
Medical Service, Michael E. De Bakey Veterans Affairs (VA) Medical Center and Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Clin Infect Dis. 2008 Apr 1;46(7):1093-100. doi: 10.1086/529201.
Human immunodeficiency virus (HIV)-infected persons have a high incidence of pneumonia and pneumococcal disease. Benefits of vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV) among these patients continue to be debated.
The impact of PPV vaccination on the incidence of pneumonia events (i.e., the composite of pneumococcal pneumonia and pneumonia due to nonspecified organisms) was examined among participants in the Veterans Aging Cohort 5-Site Study, an ongoing prospective study of HIV-infected patients matched to an HIV-uninfected control group. Dates of PPV vaccination and pneumonia were determined by retrospective review of electronic medical records. Time to events was measured for up to 2 years from PPV vaccination or from enrollment for vaccinated and unvaccinated patients, respectively. Kaplan-Meier and Cox proportional hazards regression methods were used to examine the incidence of pneumonia by HIV infection and PPV vaccination status.
Among 692 HIV-uninfected and 934 HIV-infected study participants, 59% were vaccinated with PPV. The 2-year incidence of pneumonia was 6% (97 participants developed pneumonia). HIV-infected patients had a higher rate of pneumonia (hazard ratio, 5.81; 95% confidence interval, 3.15-10.71); overall, vaccinated patients showed a trend toward lower risk of pneumonia (hazard ratio, 0.75; 95% confidence interval, 0.50-1.13). Among HIV-infected patients, after controlling for HIV-specific and other variables, vaccination significantly reduced the risk of pneumonia (hazard ratio, 0.65; 95% confidence interval, 0.42-1.00); current smoking, low hemoglobin level, and low CD4 cell count significantly increased such risk. The effect of PPV vaccination among HIV-uninfected patients was not significant.
Among HIV-infected patients, PPV vaccination offered protection against pneumonia. Smoking cessation needs to be pursued as an additional strategy for preventing pneumonia.
人类免疫缺陷病毒(HIV)感染者肺炎和肺炎球菌疾病的发病率较高。23价肺炎球菌多糖疫苗(PPV)对这些患者的疫苗接种益处仍存在争议。
在退伍军人老龄化队列5个站点研究的参与者中,研究了PPV疫苗接种对肺炎事件(即肺炎球菌肺炎和不明病原体所致肺炎的综合情况)发病率的影响,该研究是一项正在进行的针对HIV感染患者的前瞻性研究,并与未感染HIV的对照组进行匹配。通过回顾电子病历确定PPV疫苗接种日期和肺炎发病日期。分别对接种疫苗和未接种疫苗的患者,从PPV疫苗接种或入组开始测量长达2年的事件发生时间。采用Kaplan-Meier法和Cox比例风险回归方法,根据HIV感染情况和PPV疫苗接种状态来研究肺炎的发病率。
在692名未感染HIV和934名感染HIV的研究参与者中,59%接种了PPV。肺炎的2年发病率为6%(97名参与者发生肺炎)。HIV感染患者的肺炎发病率较高(风险比,5.81;95%置信区间,3.15 - 10.71);总体而言,接种疫苗的患者肺炎风险有降低趋势(风险比,0.75;95%置信区间,0.50 - 1.13)。在HIV感染患者中,在控制了HIV特异性及其他变量后,疫苗接种显著降低了肺炎风险(风险比,0.65;95%置信区间,0.42 - 1.00);当前吸烟、血红蛋白水平低和CD4细胞计数低显著增加了这种风险。PPV疫苗接种在未感染HIV患者中的效果不显著。
在HIV感染患者中,PPV疫苗接种可预防肺炎。需要将戒烟作为预防肺炎的另一项策略。